The stock of Tenax Therapeutics, Inc. (NASDAQ: TENX) closed the previous session at $2.08, meaning its value has risen 307.76% higher than its 52-week low. In intraday trading, Tenax stock hit a low of $2.03 and a high of $2.47.
A recent trading session has witnessed an intraday change of just 16.85% while TENX stock has had a 52-week high of $3.68 and a low of $0.51. An increase in TENX stock accompanied the positive results of a phase 2 study on its candidate for the treatment of cardiovascular disease.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The TENX study found what?
A specialty pharmaceutical company, Tenax Therapeutics, focuses on identifying and developing products with high unmet medical needs for cardiovascular diseases and pulmonary diseases. TENX facilitates access to world-class scientific advisory teams, which include globally recognized experts in pulmonary hypertension.
Read More
On Friday, Tenax announced that it had published positive results from its Phase 2 HELP study that examined levosimendan’s efficacy in patients with Cardiopulmonary Hypertension associated with Heart Failure.
- TENX has published a new publication titled Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Placebo-Controlled HELP Trial.
- This article was published in the Journal of the American College of Cardiology.
- Through this 6-week study, TENX examined the haemodynamics of individuals who were invasively monitored by their cardiovascular system as well as secondary clinical outcomes such as a 6-minute walk test.
- According to the TENX study published in the journal, 84% of the participants responded.
- The primary endpoint of exercise-PCWP was not significantly reduced by levosimendan, compared with placebo, but PCWP was effectively reduced across all phases of exercise.
- Compared to a control group, 6 MWD experienced a 29.5 meter improvement from the levosimendan treatment.
TENX’s further plans:
Levosimendan is currently in Phase 2 clinical trials to treat PH-HFpEF and developed by Tenax (TENX), which also has the rights to develop and commercialize this drug. Based on the TENX study’s results, further study of levosimendan in PH-HFpEF patients is warranted since this is the first drug that could demonstrate improved cardiomyopathy and improved six-minute walking distance compared to placebo.